RESUMO
As we commemorate the 70th Anniversary of the National Heart, Lung, and Blood Institute (NHLBI) and celebrate important milestones that have been achieved by the Division of Cardiovascular Sciences (DCVS), it is imperative that DCVS and the Extramural Research community at-large continue to address critical public health challenges that persist within the area of Cardiovascular Diseases (CVD). The NHLBI's Strategic Vision, developed with extensive input from the extramural research community and published in 2016, included overarching goals and strategic objectives that serve to provide a general blueprint for sustaining the legacy of the Institute by leveraging opportunities in emerging scientific areas (e.g., regenerative medicine, omics technology, data science, precision medicine, and mobile health), finding new ways to address enduring challenges (e.g., social determinants of health, health inequities, prevention, and health promotion), and training the next generation of heart, lung, blood, and sleep researchers. DCVS has developed a strategic vision implementation plan to provide a cardiovascular framing for the pursuit of the Institute's overarching goals and strategic objectives garnered from the input of the broader NHLBI community. This plan highlights six scientific focus areas that demonstrate a cross-cutting and multifaceted approach to addressing cardiovascular sciences, including 1) addressing social determinants of cardiovascular health (CVH) and health inequities, 2) enhancing resilience, 3) promoting CVH and preventing CVD Across the lifespan, 4) eliminating hypertension-related CVD, 5) reducing the burden of heart failure, and 6) preventing vascular dementia. These priorities will guide our efforts in Institute-driven activities in the coming years but will not exclude development of other novel ideas or the support of investigator-initiated grant awards. The DCVS Strategic Vision implementation plan is a living document that will evolve with iterative dialogue with the NHLBI community and adapt as the dynamic scientific landscape changes to seize emerging opportunities.
Assuntos
Cardiologia/normas , Doenças Cardiovasculares/terapia , National Heart, Lung, and Blood Institute (U.S.) , Guias de Prática Clínica como Assunto , Cardiologia/economia , Cardiologia/tendências , Doenças Cardiovasculares/epidemiologia , Doenças Cardiovasculares/etiologia , Humanos , Estados UnidosAssuntos
Doenças Cardiovasculares/economia , Doenças Cardiovasculares/terapia , Transplante de Células/economia , Apoio Financeiro , National Heart, Lung, and Blood Institute (U.S.)/economia , Animais , Transplante de Células/tendências , Terapia Baseada em Transplante de Células e Tecidos , Ensaios Clínicos como Assunto/economia , Ensaios Clínicos como Assunto/tendências , Humanos , National Heart, Lung, and Blood Institute (U.S.)/tendências , Estados UnidosAssuntos
Doenças Cardiovasculares/patologia , Imagem Molecular/métodos , Imagem Molecular/tendências , National Heart, Lung, and Blood Institute (U.S.) , Humanos , Imageamento por Ressonância Magnética/métodos , Imageamento por Ressonância Magnética/tendências , Tomografia Computadorizada de Emissão de Fóton Único/métodos , Tomografia Computadorizada de Emissão de Fóton Único/tendências , Tomografia Computadorizada por Raios X/métodos , Tomografia Computadorizada por Raios X/tendências , Ultrassonografia/métodos , Ultrassonografia/tendências , Estados UnidosRESUMO
Although myosin II is known to play an important role in cell migration, little is known about its specific functions. We have addressed the function of one of the isoforms of myosin II, myosin IIB, by analyzing the movement and mechanical characteristics of fibroblasts where this protein has been ablated by gene disruption. Myosin IIB null cells displayed multiple unstable and disorganized protrusions, although they were still able to generate a large fraction of traction forces when cultured on flexible polyacrylamide substrates. However, the traction forces were highly disorganized relative to the direction of cell migration. Analysis of cell migration patterns indicated an increase in speed and decrease in persistence, which were likely responsible for the defects in directional movements as demonstrated with Boyden chambers. In addition, unlike control cells, mutant cells failed to respond to mechanical signals such as compressing forces and changes in substrate rigidity. Immunofluorescence staining indicated that myosin IIB was localized preferentially along stress fibers in the interior region of the cell. Our results suggest that myosin IIB is involved not in propelling but in directing the cell movement, by coordinating protrusive activities and stabilizing the cell polarity.
Assuntos
Movimento Celular/fisiologia , Fibroblastos/citologia , Miosina não Muscular Tipo IIB/fisiologia , Resinas Acrílicas/química , Animais , Células Cultivadas , Embrião de Mamíferos/citologia , Fibroblastos/fisiologia , Camundongos , Mutação/genéticaRESUMO
Recent rapid advances in nanotechnology and nanoscience offer a wealth of new opportunities for diagnosis and therapy of cardiovascular, pulmonary, and hematologic diseases and sleep disorders. To review the challenges and opportunities offered by these nascent fields, the National Heart, Lung, and Blood Institute convened a Working Group on Nanotechnology. Working Group participants discussed the various aspects of nanotechnology and its applications to heart, lung, blood, and sleep (HLBS) diseases. This report summarizes their discussions according to scientific opportunities, perceived needs and barriers, specific disease examples, and recommendations on facilitating research in the field. An overarching recommendation of the Working Group was to focus on translational applications of nanotechnology to solve clinical problems. The Working Group recommended the creation of multidisciplinary research centers capable of developing applications of nanotechnology and nanoscience to HLBS research and medicine. Centers would also disseminate technology, materials, and resources and train new investigators. Individual investigators outside these centers should be encouraged to conduct research on the application of nanotechnology to biological and clinical problems. Pilot programs and developmental research are needed to attract new investigators and to stimulate creative, high-impact research. Finally, encouragement of small businesses to develop nanotechnology-based approaches to clinical problems was considered important.
Assuntos
Doenças Cardiovasculares/diagnóstico , Doenças Cardiovasculares/terapia , Diretrizes para o Planejamento em Saúde , Nanotecnologia/normas , Nanotecnologia/tendências , Animais , Técnicas Biossensoriais/tendências , Sistemas de Liberação de Medicamentos/tendências , Humanos , Comunicação Interdisciplinar , National Institutes of Health (U.S.) , Apoio à Pesquisa como Assunto , Engenharia Tecidual/tendências , Estados UnidosRESUMO
Value-Based Healthcare: Summit 2014 clearly achieved the three goals set forth at the beginning of this document. First, the live event informed and educated attendees through a discussion of the evolving value-based healthcare environment, including a collaborative effort to define the important role of cardiovascular ultrasound in that environment. Second, publication of these Summit proceedings in the Journal of the American Society of Echocardiography will inform a wider audience of the important insights gathered. Third, moving forward, the ASE will continue to build a ''living resource'' on its website, http://www.asecho.org, for clinicians, researchers, and administrators to use in advocating for the value of cardiovascular ultrasound in the new value-based healthcare environment. The ASE looks forward to incorporating many of the Summit recommendations as it works with its members, legislators, payers, hospital administrators, and researchers to demonstrate and increase the value of cardiovascular ultrasound. All Summit attendees shared in the infectious enthusiasm generated by this proactive approach to ensuring cardiovascular ultrasound's place as ''The Value Choice'' in cardiac imaging.
Assuntos
Cardiologia , Doenças Cardiovasculares/diagnóstico por imagem , Ecocardiografia/normas , Sociedades Médicas , Congressos como Assunto , Humanos , Estados UnidosAssuntos
Órgãos Bioartificiais , Insuficiência Cardíaca/cirurgia , Transplante de Coração/tendências , Coração Auxiliar , Miócitos Cardíacos/transplante , Engenharia Tecidual/tendências , Animais , Órgãos Bioartificiais/tendências , Difusão de Inovações , Insuficiência Cardíaca/diagnóstico , Insuficiência Cardíaca/fisiopatologia , Coração Auxiliar/tendências , Humanos , Desenho de Prótese , Recuperação de Função Fisiológica , Resultado do TratamentoAssuntos
Citocinas/metabolismo , Precondicionamento Isquêmico Miocárdico , Isquemia Miocárdica/imunologia , Miocárdio/imunologia , Proteínas de Ligação a DNA/metabolismo , Humanos , Interleucina-1/metabolismo , Interleucina-6/metabolismo , Janus Quinase 1 , Janus Quinase 2 , Isquemia Miocárdica/metabolismo , Miocárdio/metabolismo , Proteínas Tirosina Quinases/metabolismo , Proteínas Proto-Oncogênicas/metabolismo , Fator de Transcrição STAT1 , Transdução de Sinais/fisiologia , Fatores de Tempo , Transativadores/metabolismo , Fator de Necrose Tumoral alfa/metabolismoRESUMO
Nanotechnology provides a broad range of opportunities to develop new solutions for clinical problems. For the pulmonary field, nanotechnology promises better delivery of drugs and nucleic acid-based therapeutics to disease sites. Administration of therapeutics via inhalation provides the opportunity for direct delivery to the lung epithelium, the lining of the respiratory tract. By appropriate selection of particle size, deep lung delivery can be obtained with control of phagocytic uptake, the removal of particles by resident macrophages. Nanotechnology can also help in pulmonary therapies administered by intravenous and oral routes through targeting specific cell types and controlling bioavailability and release kinetics. In the hematology field, nanotechnology can counter multiple drug resistance in leukemia by blocking drug efflux from cancer cells, and provide effective delivery of siRNA into lymphocytes to block apoptosis in sepsis. Controlling the surface properties of materials on devices such as valves and stents promises improved biocompatibility by inhibition of thrombosis, the formation of blood clots, and regulating cell adhesion and activation. Nanoparticle-based thrombolytic agents have the potential to improve the effectiveness of clot removal. Treatment of both lung and blood diseases is also likely to benefit from nano-scaffold-based methods for controlling the differentiation and proliferation of stem and progenitor cells.
Assuntos
Sistemas de Liberação de Medicamentos/métodos , Doenças Hematológicas/terapia , Pneumopatias/terapia , Nanomedicina/métodos , Animais , Sistemas de Liberação de Medicamentos/tendências , Humanos , Nanomedicina/tendências , Nanopartículas/uso terapêutico , Nanopartículas/toxicidade , Engenharia TecidualRESUMO
Nanotechnology is poised to have an increasing impact on cardiovascular health in coming years. Diagnostically, multiplexed point-of-care devices will enable rapid genotyping and biomarker measurement to optimize and tailor therapies for the individual patient. Nanoparticle-based molecular imaging agents will take advantage of targeted agents to provide increased insight into disease pathways rather then simply providing structural and functional information. Drug delivery will be impacted by targeting of nanoparticle-encapsulated drugs to the site of action, increasing the effective concentration and decreasing systemic dosage and side effects. Controlled and tailored release of drugs from polymers will improve control of pharmacokinetics and bioavailability. The application of nanotechnology to tissue engineering will facilitate the fabrication of better tissue implants in vitro, and provide scaffolds to promote regeneration in vivo taking advantage of the body's own repair mechanisms. Medical devices will benefit from the development of nanostructured surfaces and coatings to provide better control of thrombogenicity and infection. Taken together, these new technologies have enormous potential for improving the diagnosis and treatment of cardiovascular diseases.
Assuntos
Técnicas Biossensoriais/tendências , Doenças Cardiovasculares/diagnóstico , Doenças Cardiovasculares/terapia , Portadores de Fármacos/síntese química , Nanomedicina/tendências , Nanopartículas/uso terapêutico , Técnicas Biossensoriais/instrumentação , Previsões , Nanomedicina/instrumentação , Nanopartículas/química , Estados UnidosAssuntos
Doenças Cardiovasculares/diagnóstico , Doenças Cardiovasculares/terapia , Terapia por Ultrassom , Ultrassonografia , Bioengenharia , Doenças Cardiovasculares/diagnóstico por imagem , Sistema Cardiovascular , Comunicação , Congressos como Assunto , Ecocardiografia/normas , Ecocardiografia/tendências , Ecocardiografia Doppler , Desenho de Equipamento , Humanos , Imageamento Tridimensional , Relações Interprofissionais , Sistema de Registros , Pesquisa , Software , Avaliação da Tecnologia Biomédica , Terapia Trombolítica/métodos , Ultrassonografia/tendências , Ultrassonografia de IntervençãoAssuntos
Aneurisma Aórtico/diagnóstico , Imagem Molecular/métodos , Animais , Feminino , Humanos , MasculinoRESUMO
Heart, lung and blood diseases exert an enormous toll, accounting for almost half of the deaths in the USA each year. In addition to the morbidity and mortality resulting from these diseases, there is also a high economic burden, estimated at 560 billion US dollars for 2006. Nanotechnology offers a broad range of opportunities to improve diagnosis and therapy for cardiovascular, pulmonary and hematopoietic diseases, thereby decreasing these burdens. This review will focus on four areas of particular promise for the application of nanotechnology: imaging, diagnostics and biosensors, drug delivery and therapy, and tissue engineering and repair. The goal is to summarize the current state of science and technology in these areas and to look at future directions that the field is likely to move in to enhance the diagnosis and treatment of heart, lung and blood diseases.
Assuntos
Cardiopatias/diagnóstico , Doenças Hematológicas/diagnóstico , Pneumopatias/diagnóstico , Nanotecnologia , Animais , Cardiopatias/economia , Cardiopatias/mortalidade , Cardiopatias/terapia , Doenças Hematológicas/economia , Doenças Hematológicas/mortalidade , Doenças Hematológicas/terapia , Humanos , Pneumopatias/economia , Pneumopatias/mortalidade , Pneumopatias/terapia , Nanotecnologia/economia , Nanotecnologia/tendênciasRESUMO
RAW 264.7 macrophages express nonmuscle myosin heavy chain II-A as the only significant nonmuscle myosin heavy chain isoform, with expression of nonmuscle myosin heavy chain II-B and II-C low or absent. Treatment of the cells with sodium butyrate, an inhibitor of histone deacetylase, led to the dose-dependent induction of nonmuscle myosin heavy chain II-C. Trichostatin A, another inhibitor of histone deacetylase, also induced nonmuscle myosin heavy chain II-C. Induction of nonmuscle myosin heavy chain II-C in response to these histone deacetylase inhibitors was attenuated by mithramycin, an inhibitor of Sp1 binding to GC-rich DNA sequences. Bacterial lipopolysaccharide alone had no effect on basal nonmuscle myosin heavy chain II-C expression, but attenuated butyrate-mediated induction of nonmuscle myosin heavy chain II-C. The effects of lipopolysaccharide were mimicked by the nitric oxide donors sodium nitroprusside and spermine NONOate, suggesting a role for nitric oxide in the lipopolysaccharide-mediated down-regulation of nonmuscle myosin heavy chain II-C induction. This was supported by experiments with the inducible nitric-oxide synthase inhibitor 1400W, which partially blocked the lipopolysaccharide-mediated attenuation of nonmuscle myosin heavy chain induction. 8-Bromo-cGMP had no effect on nonmuscle myosin heavy chain induction, consistent with a cGMP-independent mechanism for nitric oxide-mediated inhibition of nonmuscle myosin heavy chain II-C induction.
Assuntos
Butiratos/farmacologia , Regulação da Expressão Gênica/efeitos dos fármacos , Macrófagos/metabolismo , Cadeias Pesadas de Miosina/biossíntese , Miosina Tipo II/biossíntese , Acetiltransferases/antagonistas & inibidores , Animais , Linhagem Celular , GMP Cíclico/farmacologia , Histona Acetiltransferases , Lipopolissacarídeos/farmacologia , Camundongos , Óxido Nítrico/farmacologia , Doadores de Óxido Nítrico/farmacologia , Isoformas de Proteínas/biossíntese , Proteínas de Saccharomyces cerevisiae/antagonistas & inibidores , Fator de Transcrição Sp1/metabolismoRESUMO
Upon encountering an antigen, motile T cells stop crawling, change morphology and ultimately form an 'immunological synapse'. Although myosin motors are thought to mediate various aspects of this process, the molecules involved and their exact roles are not defined. Here we show that nonmuscle myosin heavy chain IIA, or MyH9, is the only class II myosin expressed in T cells and is associated with the uropod during crawling. MyH9 function is required for maintenance of the uropod and for T cell motility but is dispensable for synapse formation. Phosphorylation of MyH9 in its multimerization domain by T cell receptor-generated signals indicates that inactivation of this motor may be a key step in the 'stop' response during antigen recognition.